| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
The Colombian pharmaceutical market is the fifth largest in Latin America,
behind Brazil, Mexico, Argentina and Venezuela. This report is ideal for
executives wanting to understand the key drivers in the pharmaceutical market
and have access to a wealth of statistical data, including five-year market
projections. Included with the report are 3 free quarterly updated outlook
reports, enabling you to keep up to date with market developments for a year.
Includes 3 quarterly updated outlook reports!
Along with many other Latin American countries, the health sector in Colombia
has suffered from insufficient financing and a highly uneven distribution of
healthcare resources. During the 1990s, the situation changed following the
adoption of a new constitution in July 1991, which produced a far-reaching
programme of political and social reform.
In the health sector, the country embarked on an ambitious reform of the
social security system with the aim of providing universal healthcare coverage
by the year 2000. Although the reform process has been stalled by the
country's recent economic recession, Colombia remains committed to the
principle of universal healthcare coverage.
The Colombian pharmaceutical market is the fifth largest in the region, behind
Brazil, Mexico, Argentina and Venezuela. The healthcare reform programme has
been instrumental in boosting consumption of pharmaceutical products, but
growth has been largely in volume terms, due to a shift towards generics. The
majority of the market is supplied by the well-developed domestic industry.
The domestic industry is dominated by multinationals. Major indigenous
manufacturers include Bussie, Genfar, Lafrancol, La Sante, Procaps and
Tecnoquimicas. However, the country has a sizeable balance of trade deficit in
the field of pharmaceuticals, valued at US$275.8 million in 2003, partly due
to the fact that the domestic industry is heavily dependent on imports for its
raw materials.
This report comprises four main sections: Pharma Market Outlook, Background
Data, Healthcare System, and Accessing the Pharmaceutical Market. The Outlook
section provides analysis of the market and five-year market forecasts,
national data projections and key market developments. Other sections provide
a wealth of background and market access information, including pharmaceutical
regulation, pricing & reimbursement, population trends, morbidity and
mortality, health expenditure, organisation & administration, hospital
services, ambulatory care, medical personnel, trade data and essential
industry contacts.
TABLE OF CONTENTS
EXECUTIVE SUMMARY
PHARMACEUTICAL MARKET
- Current Size
- Projections
- Market Structure
- Pharmacy Market
- Institutional Market
- Prescription Medicines
- Generic Medicines
- OTC Medicines
- Domestic Production
- Imports
- Research & Development
- Exports
- Balance of Trade
- Market Developments
- The national pharmaceutical policy (PFN)
- Advances in intellectual property rights as part of the US-Andean Free
Trade Agreement (FTA)
- Price controls on oncology medicines
- HIV/AIDS development programmes
- The arrival of foreign pharmacy chains
- The erectile dysfunction market
- The fall of counterfeit drugs
- MPS' plans to merge INVIMA with two superintendencies
KEY NATIONAL DATA PROJECTIONS
SOURCES
|
